Recent Advances in Medical Therapy for Urological Cancers

Recent Advances in Medical Therapy for Urological Cancers

The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play important roles in these malignancies. However, i...

Full description

Bibliographic Details
Main Authors:	Takeshi Yuasa, Tetsuya Urasaki, Ryosuke Oki
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Oncology
Subjects:	immune checkpoint inhibitor PARP inhibitor olaparib antibody-drug conjugate androgen receptor axis targeted agent enfortumab vedotin
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.746922/full

Similar Items

Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
by: Olga Bednova, et al.
Published: (2020-10-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023-03-01)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
by: Jain RK, et al.
Published: (2020-09-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
by: Nobuaki Matsubara, et al.
Published: (2023-02-01)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
by: Marco Audisio, et al.
Published: (2022-05-01)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
by: Takamasa Homma, et al.
Published: (2023-10-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer
by: Mariko Kotono, et al.
Published: (2024-03-01)

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside
by: Antonio Ungaro, et al.
Published: (2022-02-01)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01)

The successful management of SJS/TEN secondary to enfortumab vedotin therapy
by: Rhea Singh, BS, et al.
Published: (2022-06-01)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
by: Tanya Jindal, et al.
Published: (2023-04-01)

Mechanisms of Resistance to Antibody-Drug Conjugates
by: Rita Khoury, et al.
Published: (2023-06-01)

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
by: Akinori Minato, et al.
Published: (2024-02-01)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
by: Brigida Anna Maiorano, et al.
Published: (2023-09-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
by: Takashi Kawahara, et al.
Published: (2023-08-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
by: Alecu I, et al.
Published: (2018-02-01)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
by: Anna D. Staniszewska, et al.
Published: (2022-12-01)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
by: Kaylyn R. Collette, et al.
Published: (2022-05-01)

Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update
by: Alvin Jun Xing Lee, et al.
Published: (2020-12-01)

Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01)

NECTIN4 Expression in Extramammary Paget’s Disease: Implication of a New Therapeutic Target
by: Maho Murata, et al.
Published: (2020-08-01)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021-02-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
by: Isabella Faraoni, et al.
Published: (2019-09-01)

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer
by: An-Jin Wang, et al.
Published: (2022-12-01)

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma
by: Arash Navran, et al.
Published: (2024-01-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study
by: Hamid Sheikh, et al.
Published: (2023-05-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
by: Shu Y, et al.
Published: (2022-06-01)

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Yan Wei, et al.
Published: (2024-03-01)